Literature DB >> 26376351

Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.

Michael S Isakoff1, Robert Goldsby2, Doojduen Villaluna3, Mark D Krailo3,4, Richard Gorlick5, John J Doski6, Richard B Womer7, Katherine A Janeway8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26376351      PMCID： PMC4830388          DOI： 10.1002/pbc.25754

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  6 in total

1.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.

Authors:  Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

2.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

3.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

4.  Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.

Authors:  Anne B Warwick; Suman Malempati; Mark Krailo; Allen Melemed; Richard Gorlick; Matthew M Ames; Stephanie L Safgren; Peter C Adamson; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2012-06-28       Impact factor: 3.167

5.  Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.

Authors:  Shana Jacobs; Elizabeth Fox; Mark Krailo; Gwen Hartley; Fariba Navid; Leonard Wexler; Susan M Blaney; Anne Goodwin; Wendy Goodspeed; Frank M Balis; Peter C Adamson; Brigitte C Widemann
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

6.  Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Catherine A Billups; Christopher Desjardins; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-03-28       Impact factor: 3.167
  6 in total
  7 in total

Review 1.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

Review 2.  Future directions in the treatment of osteosarcoma.

Authors:  Michael W Bishop; Katherine A Janeway; Richard Gorlick
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

Review 3.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 4.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

Review 5.  Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.

Authors:  Damon R Reed; Pooja Hingorani; Peter M Anderson
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

Authors:  Michael S Isakoff; Robert Goldsby; Doojduen Villaluna; Mark D Krailo; Pooja Hingorani; Anderson Collier; Carol D Morris; E Anders Kolb; John J Doski; Richard B Womer; Richard Gorlick; Katherine A Janeway
Journal:  Pediatr Blood Cancer       Date:  2018-10-30       Impact factor: 3.167

7.  Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.

Authors:  Amy K LeBlanc; Timothy M Fan; Christina N Mazcko; Aswini Cherukuri; Erika P Berger; William C Kisseberth; Megan E Brown; Susan E Lana; Kristen Weishaar; Brian K Flesner; Jeffrey N Bryan; David M Vail; Jenna H Burton; Jennifer L Willcox; Anthony J Mutsaers; J Paul Woods; Nicole C Northrup; Corey Saba; Kaitlin M Curran; Haley Leeper; Heather Wilson-Robles; Brandan G Wustefeld-Janssens; Stephanie Lindley; Annette N Smith; Nikolaos Dervisis; Shawna Klahn; Mary Lynn Higginbotham; Raelene M Wouda; Erika Krick; Jennifer A Mahoney; Cheryl A London; Lisa G Barber; Cheryl E Balkman; Angela L McCleary-Wheeler; Steven E Suter; Olya Martin; Antonella Borgatti; Kristine Burgess; Michael O Childress; Janean L Fidel; Sara D Allstadt; Daniel L Gustafson; Laura E Selmic; Chand Khanna
Journal:  Clin Cancer Res       Date:  2021-03-22       Impact factor: 13.801
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.